DelveInsight’s, “Respiratory Syncytial Virus Pipeline Insight 2023” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Respiratory Syncytial Virus pipeline landscape. It covers the Respiratory Syncytial Virus pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Respiratory Syncytial Virus pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Respiratory Syncytial Virus Pipeline Report

• DelveInsight’s Respiratory Syncytial Virus pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Respiratory Syncytial Virus treatment.
• The leading companies working in the Respiratory Syncytial Virus Market include GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, AlloVir Inc., Anima Biotech Inc., Atea Pharmaceuticals Inc., Atriva Therapeutics, Calder Biosciences Inc., Cidara Therapeutics Inc., Clover Biopharmaceuticals, Curevac AG, Enyo Pharma SA, HanaVax Inc., Icosavax Inc., IDBiologics Inc., Pneumagen Ltd, Riboscience LLC, Signia Therapeutics, and others.
• Promising Respiratory Syncytial Virus Pipeline Therapies in the various stages of development include Nirsevimab, EDP-938, AK0529, ALN-RSV01, ALS-008176, GS-5806, and others.
• August 2023: Sanofi announced a study of phase 3 clinical trails for Nirsevimab. The purpose of this study is to determine the efficacy and safety of a single intramuscular (IM) dose of nirsevimab, compared to no intervention, for the prevention of hospitalizations due to lower respiratory tract infection (LRTI) caused by confirmed RSV infection (henceforth referred to as RSV LRTI hospitalizations) in all infants under 12 months of age who are not eligible to receive palivizumab.
• September 2023: AstraZeneca announced a study of phase 3 clinical trials for Nirsevimab. The purpose of this study is to measure the safety, PK, occurrence of ADA to nirsevimab, and anti-RSV neutralizing Ab in Japanese children with certain health conditions or pre-term infants aged ≤12 months.

 

Request a sample and discover the recent advances in Respiratory Syncytial Virus Treatment Drugs @ Respiratory Syncytial Virus Pipeline Report

 

In the Respiratory Syncytial Virus pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Respiratory Syncytial Virus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Respiratory Syncytial Virus Overview

Respiratory syncytial virus (RSV) is a very common cause of respiratory tract infection, particularly in children. Nearly all children have been infected by age 4 years, many in the first year of life. Infection does not provide complete immunity, so reinfection is common, although usually less serious.

 

Find out more about Respiratory Syncytial Virus Treatment Drugs @ Drugs for Respiratory Syncytial Virus Treatment

 

Respiratory Syncytial Virus Emerging Drugs Profile

• GSK3844766A: GlaxoSmithKline
• Nirsevimab (MEDI-8897): MedImmune
• Sisunatovir: ReViral

 

Respiratory Syncytial Virus Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the Respiratory Syncytial Virus. The Respiratory Syncytial Virus companies which have their Respiratory Syncytial Virus (RSV) drug candidates in the most advanced stage, i.e. phase III include, GlaxoSmithKline.

 

Learn more about the emerging Respiratory Syncytial Virus Pipeline Therapies @ Respiratory Syncytial Virus Clinical Trials Assessment

 

Scope of the Respiratory Syncytial Virus Pipeline Report

• Coverage- Global
• Respiratory Syncytial Virus Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Respiratory Syncytial Virus Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Respiratory Syncytial Virus Companies- GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, AlloVir Inc., Anima Biotech Inc., Atea Pharmaceuticals Inc., Atriva Therapeutics, Calder Biosciences Inc., Cidara Therapeutics Inc., Clover Biopharmaceuticals, Curevac AG, Enyo Pharma SA, HanaVax Inc., Icosavax Inc., IDBiologics Inc., Pneumagen Ltd, Riboscience LLC, Signia Therapeutics, and others.
• Respiratory Syncytial Virus Pipeline Therapies- Nirsevimab, EDP-938, AK0529, ALN-RSV01, ALS-008176, GS-5806, and others.

 

Dive deep into rich insights for new drugs for Respiratory Syncytial Virus treatment, Visit @ Respiratory Syncytial Virus Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Respiratory Syncytial Virus (RSV): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Respiratory Syncytial Virus (RSV) – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Respiratory Syncytial Virus (RSV) Collaboration Deals
9. Late Stage Products (Phase III)
10. GSK3844766A: GlaxoSmithKline
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. EDP 938: Enanta Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. mRNA-1345: Moderna Therapeutics
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. AR-201: Aridis Pharmaceuticals
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Respiratory Syncytial Virus (RSV) Key Companies
23. Respiratory Syncytial Virus (RSV) Key Products
24. Respiratory Syncytial Virus (RSV)- Unmet Needs
25. Respiratory Syncytial Virus (RSV)- Market Drivers and Barriers
26. Respiratory Syncytial Virus (RSV)- Future Perspectives and Conclusion
27. Respiratory Syncytial Virus (RSV) Analyst Views
28. Respiratory Syncytial Virus (RSV) Key Companies
29. Appendix

 

For further information on the Respiratory Syncytial Virus pipeline therapeutics, reach out to Respiratory Syncytial Virus Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking